• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Study: Wearables Increased Referral Rate for Advanced Therapy in Parkinson’s Disease

by Fred Pennic 07/21/2016 Leave a Comment

Wearables in Parkinson’s Disease

Great Lakes NeuroTech has completed and published a clinical study validating that remote monitoring with wearable, objective sensors can lead to an increased referral rate for advanced therapies in Parkinson’s disease.

Published in The Journal of Parkinson’s Disease, the protocol followed 40 patients with Parkinson’s disease randomized into two groups for one year.  The control group received standard care for assessing Parkinson’s disease, while the other used wearable, objective sensors (Kinesia™) in the home environment.

Kinesia ONE uses an app and wireless sensors to objectively measures movement disorders such as Parkinson’s Disease. The sensor and app measures tremor, bradykinesia, and dyskinesia Additionally, during specific tasks, the system can be integrated into clinical trials or patient care.

For the Kinesia group, clinicians remotely viewed reports detailing motor symptoms and dyskinesia throughout the day via a web portal to aid in disease management decisions.  The results demonstrated a clinician was 5 times more likely to recommend a patient for an advanced therapy such as deep brain stimulation (DBS) or an implantable medication pump when given access to objective, remote monitoring reports.  The referral rate for the Kinesia group was 63.6% compared to 11.8% in the standard care group.

The study demonstrated that, when measured remotely, specific variables such as symptom severity and fluctuations of motor symptoms could provide key information to clinicians about when it was time to consider an advanced therapy.

“An important reason we developed and validated our Kinesia technology was to give clinicians a window into what happens when individuals with Parkinson’s disease leave the clinic,” says Dustin Heldman, Biomedical Research Manager in a statement. “The results of this study are advancing our technology beyond the initial building blocks of algorithm validation and usability.  We are now seeing the technology deployed and validated in targeted applications to help guide clinical decision making and improve patient care.  Getting the right therapy to patients at the right time is one of those targeted apps , in which Kinesia can have a significant positive impact.”  

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Q/A: Oatmeal Health Co-Founder Talks AI-Enabled Cancer Screening for the Underserved

Q/A: Oatmeal Health Co-Founder Talks AI-Enabled Cancer Screening for the Underserved

GE HealthCare to Acquire Caption Health

GE HealthCare to Acquire Caption Health to Expand AI-Guided Ultrasounds

Epic, Impact Advisors, Nordic, Chartis Named 2023 Overall Best in KLAS® Awards

Epic, Impact Advisors, Nordic, Chartis Named 2023 Overall Best in KLAS® Awards

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |